ArticleMolecular genetics and genomics : MGG2026
HOXC9 transcriptionally activates NRP1 to promote cell malignant progression and immune evasion in colorectal cancer.
Article in Molecular genetics and genomics : MGG, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Transcription factor homeobox C9 (HOXC9) has been reported to be up-regulated and associated with poor prognosis in colorectal cancer (CRC). This study focused on the regulatory role and molecular mechanism of HOXC9 in CRC progression and immune response. Differential analysis from the GSE25070 dataset was performed. The mRNA and protein levels of target genes were measured using qPCR and Western blotting. Malignant behaviors in LoVo and Caco2 cells were assessed using colony formation assay, transwell assay and tumor sphere formation assay. Programmed death ligand 1 (PD-L1) expression on cell surface was detected using flow cytometry. LoVo and Caco2 cells were co-cultured with CD8 + T cells, followed by apoptosis detection using flow cytometry and quantification of immune-related mRNA using qPCR. Role of HOXC9 in vivo was explored through xenograft tumor assay. Interaction between HOXC9 and neuropilin 1 (NRP1) was validated via chromatin immunoprecipitation (ChIP) and dual-luciferase reporter assay. HOXC9 was upregulated and predicted a poor prognosis in CRC. Silencing HOXC9 suppressed CRC cell proliferation, migration, invasion, cell stemness, down-regulated PD-L1 expression and promoted anti-tumor immune function of CD8 + T cells. HOXC9 knockdown reduced CRC tumor growth and PD-L1 expression in vivo. HOXC9 elevated NRP1 expression via transcriptional activation of NRP1. NRP1 overexpression could reverse CRC progression inhibition and immune function enhancement caused by HOXC9 downregulation. These findings elucidate a specific mechanism whereby HOXC9 transcriptionally activates NRP1, thereby contributing to CRC malignant development and immune evasion.
Indexed as
Identifiers
42637860What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.